Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Debt Repayments (2021 - 2023)

InMed Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $94400.0 for Q4 2023.

  • For Q4 2023, Long-Term Debt Repayments fell 12.76% year-over-year to $94400.0; the TTM value through Dec 2023 reached $410572.0, up 28.8%, while the annual FY2023 figure was $426575.0, 24.78% up from the prior year.
  • Long-Term Debt Repayments reached $94400.0 in Q4 2023 per INM's latest filing, down from $98709.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $214791.0 in Q4 2021 to a low of $17411.0 in Q3 2021.
  • Average Long-Term Debt Repayments over 3 years is $96154.6, with a median of $99806.0 recorded in 2022.
  • The largest YoY upside for Long-Term Debt Repayments was 479.54% in 2022 against a maximum downside of 49.62% in 2022.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $214791.0 in 2021, then plummeted by 49.62% to $108209.0 in 2022, then fell by 12.76% to $94400.0 in 2023.
  • Per Business Quant, the three most recent readings for INM's Long-Term Debt Repayments are $94400.0 (Q4 2023), $98709.0 (Q3 2023), and $109085.0 (Q2 2023).